About Dr. Li Xiaoying
Dr. Li Xiaoying (李小英) is one of China's most distinguished endocrinologists and the Director of the Department of Endocrinology and Metabolism at Zhongshan Hospital, affiliated with Fudan University. She holds the title of Chief Physician and Professor and is nationally recognized as a leading authority on diabetes, obesity, and metabolic syndrome.
Over a career spanning more than three decades, Dr. Li has established Zhongshan Hospital's Endocrinology Department as one of the premier metabolic disease centers in China. She is particularly renowned for her expertise in type 2 diabetes management, obesity and metabolic surgery, and diabetic complications — areas where her contributions have shaped national clinical guidelines and influenced endocrinology practice across China.
International patients with diabetes, obesity, thyroid disease, or other endocrine conditions consistently identify Dr. Li as one of Shanghai's top endocrinologists for both primary treatment and expert second opinions.
Professional Positions and Affiliations
- Director, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University
- Chairwoman, Obesity and Metabolic Disease Committee, Chinese Diabetes Society
- Vice Chairwoman, Chinese Diabetes Society
- Editorial Board Member: Diabetes Care, Obesity Reviews, Journal of Diabetes Investigation
- Member, European Association for the Study of Diabetes (EASD)
- Member, American Diabetes Association (ADA)
- Member, International Diabetes Federation (IDF)
Specialties and Clinical Expertise
- Type 2 Diabetes — comprehensive glycemic management; GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide); SGLT-2 inhibitors (empagliflozin, dapagliflozin); DPP-4 inhibitors; insulin optimization; continuous glucose monitoring (CGM) and closed-loop insulin delivery; cardiovascular and renal risk reduction
- Type 1 Diabetes — insulin pump therapy (CSII), CGM, hybrid closed-loop systems; islet transplantation coordination
- Obesity and Metabolic Syndrome — medical weight management (semaglutide, tirzepatide); bariatric surgery evaluation and post-operative endocrine management; metabolic syndrome risk reduction
- Diabetic Complications — diabetic nephropathy, retinopathy, neuropathy, and foot disease; multidisciplinary complication management
- Thyroid Disease — hypothyroidism, hyperthyroidism (Graves' disease), thyroid nodules, and thyroid cancer follow-up; radioiodine therapy coordination
- Polycystic Ovary Syndrome (PCOS) — insulin resistance management, ovulation induction coordination, and metabolic risk reduction
- Osteoporosis — DEXA scanning, fracture risk assessment, and anti-osteoporotic therapy
- Adrenal and Pituitary Disorders — adrenal incidentaloma workup, Cushing's syndrome screening, and pituitary adenoma management
Academic and Research Contributions
Dr. Li Xiaoying has published over 170 peer-reviewed papers in leading international endocrinology and diabetes journals, with a particular focus on the pathophysiology of type 2 diabetes in Chinese patients, the metabolic effects of GLP-1 receptor agonists, and the outcomes of bariatric surgery in Chinese obese patients. Her research on the distinct metabolic phenotype of Chinese patients with type 2 diabetes — who tend to develop diabetes at lower BMI than Western patients due to greater visceral adiposity — has been widely cited and has influenced international diabetes guidelines for Asian populations.
She chairs the Obesity and Metabolic Disease Committee of the Chinese Diabetes Society and has been a lead author on China's national obesity management guidelines. She is a regular invited speaker at EASD, ADA, and the IDF World Diabetes Congress.
Why International Patients Choose Dr. Li Xiaoying
- China's leading obesity and metabolic disease specialist — Chairwoman of China's national obesity committee
- GLP-1 and SGLT-2 therapy expertise — semaglutide, tirzepatide, and empagliflozin for diabetes and weight management
- Asian diabetes phenotype expertise — understanding of diabetes at lower BMI in Asian patients
- Diabetes Care editorial board — at the forefront of global diabetes research
- EASD and ADA member — aligned with international diabetes management standards
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Zhongshan Hospital, 180 Fenglin Road, Xuhui District, Shanghai
- Appointment Lead Time: 2″3 weeks; urgent cases expedited through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Pre-consultation: Overseas lab results, CGM data, and prior treatment records reviewed remotely through CMCS
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking endocrinology care with Dr. Li Xiaoying at Zhongshan Hospital. Our services include priority appointment booking, medical record and lab result translation, remote pre-consultation review, on-site interpretation, accommodation coordination, insurance liaison, and post-treatment follow-up with your home country endocrinologist.
📧 Contact us: contract@medicalsh.com
🌐 medicalsh.com
댓글 0개